Contrasting Curative Biotechnology (OTCMKTS:CUBT) & BioRestorative Therapies (NASDAQ:BRTX)

Curative Biotechnology (OTCMKTS:CUBT) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Curative Biotechnology and BioRestorative Therapies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	N/A
BioRestorative Therapies	0	0	1	0	3.00

BioRestorative Therapies has a consensus target price of $15.00, suggesting a potential upside of 657.58%. Given BioRestorative Therapies’ higher possible upside, analysts plainly believe BioRestorative Therapies is more favorable than Curative Biotechnology.

Earnings & Valuation

This table compares Curative Biotechnology and BioRestorative Therapies’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
BioRestorative Therapies	$149,500.00	89.66	-$14.41 million	($2.31)	-0.86

Curative Biotechnology has higher earnings, but lower revenue than BioRestorative Therapies.

Insider and Institutional Ownership

69.4% of BioRestorative Therapies shares are owned by institutional investors. 21.6% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Curative Biotechnology and BioRestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
BioRestorative Therapies	-7,303.33%	-96.09%	-85.36%

Risk and Volatility

Curative Biotechnology has a beta of -17.31, meaning that its stock price is 1,831% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 61.71, meaning that its stock price is 6,071% more volatile than the S&P 500.

Summary

BioRestorative Therapies beats Curative Biotechnology on 6 of the 9 factors compared between the two stocks.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.